LUWI is a modern STI preventing contraceptive that is OTC, on demand, hormone-free, latex-free, thinner than a condom, and made for women to have an option that feels better than condoms; First market is B2B2C with 1.5M units under LOI ($1.8M rev) from university health centers and distributors with pipeline of $12M. LUWI is on track to complete FDA 510k Class II regulatory clearance Jan 2025. IP is to be filed on product and manufacturing.